Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)

BACKGROUND: Patients with advanced biliary tract cancer who progress on first-line therapy have limited treatment options. The TreeTopp study assessed varlitinib, a reversible small molecule pan-human epidermal growth factor receptor inhibitor, plus capecitabine in previously treated advanced biliar...

Descripción completa

Detalles Bibliográficos
Autores principales: Javle, M.M., Oh, D.-Y., Ikeda, M., Yong, W.-P., Hsu, K., Lindmark, B., McIntyre, N., Firth, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685988/
https://www.ncbi.nlm.nih.gov/pubmed/34922298
http://dx.doi.org/10.1016/j.esmoop.2021.100314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685988/
https://www.ncbi.nlm.nih.gov/pubmed/34922298
http://dx.doi.org/10.1016/j.esmoop.2021.100314

Ejemplares similares